Aging, Biomarker, Ceruloplasmin, Copper, Diminished Ovarian Reserve, Premature Ovarian Insufficiency
Conditions
Brief summary
The goal of this observational study is to find differences in serum biomarkers between ovarian function and normal individuals.
Detailed description
Collect the serum of the observation group and control group volunteers, and measure the levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. in the serum.
Interventions
DIAGNOSTIC_TESTblood test
Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.
Sponsors
Shi Yun
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. The selection criteria for healthy individuals are follows. * women aged 18-45. * Basic FSH\<10IU/L, and AMH is within the normal range. * Regular menstruation. * Agree and sign an informed consent form. 2. The selection criteria for DOR patients are follows. * women aged 18-45. * For two consecutive menstrual cycles, 25 ≥ basal FSH ≥ 10IU/L or AMH\<1.1ng/ml. * Agree and sign an informed consent form. 3. Selection criteria for POI patients are follows. * 18 ≤ females aged \<40 years old. * Two consecutive menstrual cycles with basal FSH\>25IU/L or AMH\<1.1ng/ml. * Agree and sign an informed consent form.
Exclusion criteria
1. Patients with congenital gonadal developmental abnormalities or a family history similar to early menopause. 2. Patients with acquired organic lesions or decreased ovarian function caused by ovarian surgery. 3. Patients who have undergone artificial cycle therapy with Western medicine or other endocrine treatments within the past three months. 4. Patients with severe primary diseases and mental disorders such as crdiovascular, cerebrovascular, liver, kidney, and hematopoietic system. 5. Patients during lactation or pregnancy. 6. Patients who are allergic to the drugs used in this study or have a history of allergic reactions to traditional Chinese medicine. Those who meet any of the above 5 criteria for DOR and POI will be excluded and not included in this study. The
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Iron ion | On the 2~4th day of menstruation (amenorrhea patients on the enrolled week) | the level of Iron ion in blood sample |
| ceruloplasmin, CP | On the 2~4th day of menstruation (amenorrhea patientson the enrolled week) | the level of ceruloplasmin in blood sample |
| CuZn-Superoxide Dismutase, CuZn-SOD/SOD1 | On the 2~4th day of menstruation (amenorrhea patients on the enrolled week) | the level of CuZn-SOD/SOD1 in blood sample |
| Malondialdehyde，MDA | On the 2~4th day of menstruation (amenorrhea patients on the enrolled week) | the level of MDA in blood sample |
| copper | On the 2~4th day of menstruation (amenorrhea patients on the enrolled week) | the level of copper in blood sample |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| other relative biomarkers about copper/iron metabolism and oxidative stress | On the 2~4th day of menstruation (amenorrhea patients on the enrolled week) | depending on the results of the five biomarkers above |
Countries
China
Contacts
Primary ContactYun Shi, PhD
Backup ContactKe Xu, Master
Outcome results
None listed